IDH1 and acute myeloid leukemia: It has successfully progressed to phase III clinical trials in several indications, including cholangiocarcinoma, acute myeloid leukaemia (AML), and other solid tumours.25 Other examples of MT-IDH1 inhibitors include olutasidenib (FT-2102), IDH305, vorasidenib (AG-881), GSK2857916, and BAY1436032.